Improving Surgical Oncology

A medical device company with the goal to improve the surgical care for cancer patients.

Our Goal

SurGuide support surgeons in their aim to achieve complete tumor removal, which is the biggest challenge in cancer surgery. Incomplete tumor removal, negatively affects patient outcome and necessitates additional treatment¹.

SurGuide’s technology addresses the problem that the information about the result of the operation becomes available only after several days. SurGuide’s technology will enable inspection of the resected tissue to determine if a tumor has been completely removed.

The result of this inspection is reported to the surgeon, while the patient is still in the operating room. The report shows at which locations the tumor has not been completely removed. Based on this critical feedback the surgeon can decide to perform an additional resection at the indicated locations.

In this way SurGuide’s technology will help to increase the rate of complete tumor resections.

Oral cavity cancer

SurGuide’s first focus is oral cavity cancer. Complete tumor removal in oral cavity cancer surgery requires resection of the tumor with a margin of more than 5mm of surrounding healthy tissue². Our technology is not limited to oral cavity cancer. Other cancer types will follow after successful market introduction.

350.000 new patients / year

~350.000 new patients are diagnosed with oral cavity cancer each year. The average 5-yr survival rate is <50%, and is particularly low in advanced stages of disease^3,4.

In <20%, the tumor is adequately removed

Less than 20% of surgical procedures for oral cancer result in complete tumor removal, according to the latest publications. This results in poorer prognosis and necessitates additional treatment with radiotherapy or chemotherapy^5,6.

MarginGuide

Take a look at the video to learn more about SurGuide and our mission to improve the surgical care for oncology patients!

MarginGuide is currently under development in collaboration with RiverD International, art photonics and the Erasmus-university Medical Center.

News

Raising awareness for cancer in the Head & Neck region

Head & Neck cancer is the seventh most common type of cancer in Europe[1]. Head & Neck cancer includes o.a. Oral Cavity Cancer. More than 75%

2 October 2020

Specimen-driven intraoperative assessment of resection margins should be standard of care for oral cancer patients

The Erasmus-university Medical Center recently published a review on the methods for intraoperative margin assessment. The review recommends the specimen-driven approach, which corresponds with the

18 September 2020

Anand Manichand joins SurGuide B.V. as Development and Commercial lead

Anand Manichand, takes on the role of Development and Commercial lead and thereby strengthens the team of SurGuide, a Rotterdam based MedTech start-up. In his

14 September 2020